date,title,source
Oct-17-18,Duchenne biotech Sarepta to open gene therapy facility in Ohio,American City Business Journals
Oct-17-18,Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect,Zacks
Oct-17-18,Sarepta Announces Agreement With Lysogene for Gene Therapy,Zacks
Oct-18-18,"Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018",GlobeNewswire
Oct-23-18,"Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT",Zacks
Oct-24-18,"Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Oct-24-18,Sarepta Therapeutics: 3Q Earnings Snapshot,Associated Press
Oct-24-18,Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments,GlobeNewswire
Oct-24-18,Q3 Earnings Preview For Sarepta Therapeutics,Benzinga
Oct-25-18,Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT,Thomson Reuters StreetEvents
Oct-25-18,"Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up",Zacks
Oct-26-18,Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT,Thomson Reuters StreetEvents
Oct-29-18,7 Rising Healthcare Stocks to Consider,InvestorPlace
Oct-30-18,Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares,GuruFocus.com
Oct-30-18,"Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Oct-31-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Oct-31-18,Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics,ACCESSWIRE
Nov-05-18,Weekly CEO Buys Highlight,GuruFocus.com
Nov-06-18,Hedge Funds Just Stormed Into This Red-Hot Biotech Company,Insider Monkey
Nov-06-18,Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options,Zacks
Nov-07-18,"Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock",GlobeNewswire
Nov-08-18,"Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock",GlobeNewswire
Nov-12-18,These Biopharmas Could Cure Genetic Diseases  At $5 Million Apiece,Investor's Business Daily
Nov-16-18,Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics,ACCESSWIRE
Nov-23-18,Sarepta Stock More Than Doubles This Year So Far: Here's Why,Zacks
Nov-30-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Dec-06-18,Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics,ACCESSWIRE
Dec-07-18,"New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices  Consolidated Revenues, Company Growth, and Expectations for 2018",GlobeNewswire
Dec-11-18,"Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors",GlobeNewswire
Dec-12-18,"Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)",Simply Wall St.
Dec-13-18,"Ghost Tree Capitals AUM, Returns and Holdings",Insider Monkey
Dec-20-18,Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53,GlobeNewswire
Dec-24-18,Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019,Investor's Business Daily
Dec-31-18,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Jan-02-19,Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy,GlobeNewswire
Jan-02-19,Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference,GlobeNewswire
Jan-03-19,Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply,Zacks
Jan-04-19,Here's Why Sarepta Therapeutics Fell 15.7% in December,Motley Fool
Jan-08-19,"Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track",Benzinga
Jan-08-19,4 Biotechs That Are Potential Buyouts Post Celgene Deal,Zacks
Jan-11-19,Why Sarepta Therapeutics Stock Is Starting to Shine Again,InvestorPlace
Jan-14-19,"Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Jan-15-19,Heres your guide to the upcoming biotechnology takeover wave,MarketWatch
Jan-15-19,FDA pilot program could help Wave avoid orphan-drug pitfalls,American City Business Journals
Jan-16-19,Here are top analysts' 5 favorite growth stocks for 2019,CNBC
Jan-31-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Jan-31-19,Fear of Missing Out Is the Main Driving Force in This Market,TheStreet.com
Jan-31-19,"Your first trade for Thursday, January 31",CNBC
Jan-31-19,Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics,ACCESSWIRE
Feb-01-19,"Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?",Simply Wall St.
Feb-01-19,6 Biotech Stocks to Watch Now,Motley Fool
Feb-05-19,Weekly CFO Sells Highlight,GuruFocus.com
Feb-07-19,What Solid Biosciences' First Failure Means for Sarepta Therapeutics,Motley Fool
Feb-07-19,Solid Biosciences shares drop 70% on disappointing Duchenne data,American City Business Journals
Feb-07-19,Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains,Bloomberg
Feb-11-19,Weekly CFO Sells Highlight,GuruFocus.com
Feb-11-19,Implied Volatility Surging for Sarepta (SRPT) Stock Options,Zacks
Feb-14-19,"Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)",GlobeNewswire
Feb-14-19,Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53,GlobeNewswire
Feb-15-19,Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review,Zacks
Feb-20-19,"Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019",GlobeNewswire
Feb-25-19,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,Benzinga
Feb-25-19,MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks,Investing.com
Feb-26-19,"Jim Cramer Weighs In On Foot Locker, Cisco And More",Benzinga
Feb-27-19,[$$] Sarepta Acquires Gene-Therapy Startup Myonexus Therapeutics for $165 Million,The Wall Street Journal
Feb-27-19,Gene Therapy Space Heats Up As This Biotech Chases Down A Breakout,Investor's Business Daily
Feb-27-19,Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments,GlobeNewswire
Feb-27-19,"Sarepta To Pay $165M To Buy Out Myonexus, Reports Positive Results For Muscular Dystrophy Trial Results",Benzinga
Feb-27-19,"Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition",TheStreet.com
Feb-27-19,Sarepta doubles down on gene therapies after early Limb-Girdle data,American City Business Journals
Feb-27-19,"Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy",GlobeNewswire
Feb-27-19,Sarepta stock up 3% after announcing acquisition of gene-therapy company Myonexus,MarketWatch
Feb-27-19,Sarepta to buy Myonexus for $165 mln in gene therapy push,Reuters
Feb-27-19,Sarepta to buy gene therapy developer Myonexus for $165 mln,Reuters
Feb-27-19,Sarepta Exercises Option to Acquire Myonexus Therapeutics,GlobeNewswire
Feb-28-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Feb-28-19,Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development,Benzinga
Feb-28-19,"Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up",Zacks
Feb-28-19,"Too Much Talking, Not Enough Action",Zacks
Feb-28-19,Sarepta (SRPT) Jumps: Stock Rises 8.3%,Zacks
Feb-28-19,"Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program",GlobeNewswire
Feb-28-19,Nationwide Children's gene therapy spinoff acquired for $165M after promising results,American City Business Journals
Feb-28-19,Edited Transcript of SRPT earnings conference call or presentation 27-Feb-19 9:30pm GMT,Thomson Reuters StreetEvents
Mar-01-19,Why Big Pharma Is Diving Into Gene Therapy,Barrons.com
Mar-04-19,Why NOW Is the Time to Buy Gene Therapy Stocks,InvestorPlace
Mar-05-19,Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock,GlobeNewswire
Mar-05-19,"Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock",GlobeNewswire
Mar-06-19,"More biotech takeover targets coming, says Jefferies top analyst",CNBC Videos
Mar-06-19,"Why NIO, Brown-Forman, and Sarepta Therapeutics Slumped Today",Motley Fool
Mar-06-19,Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today,InvestorPlace
Mar-06-19,"Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics  Future Expectations, Projections Moving into 2019",GlobeNewswire
Mar-15-19,Sarepta Therapeutics' Charts Look Risky,TheStreet.com
Mar-25-19,Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program,GlobeNewswire
Mar-26-19,Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now?,Motley Fool
Mar-27-19,8 Genomic Testing Stocks That Can Ease the Sting of Theranos,InvestorPlace
Mar-28-19,How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key Market,Investor's Business Daily
Mar-28-19,Sarepta plans second Duchenne drug application this year,American City Business Journals
Mar-28-19,Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug,MarketWatch
Mar-28-19,Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study,GlobeNewswire
Mar-29-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Apr-03-19,Ex-Sarepta execs join new Atlas-backed muscular disease startup fueled by $50M,American City Business Journals
Apr-08-19,4 Gene Therapy Players Likely to Become Buyout Targets in 2019,Zacks
Apr-08-19,Sarepta Therapeutics Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference,GlobeNewswire
Apr-17-19,Wave Life Sciences Plunges After DMD Study Data Readout,Zacks
Apr-22-19,Pfizer Stock Suffers From an Underappreciated Drugs Pipeline,InvestorPlace
Apr-23-19,3 Stocks Warren Buffett Would Love,Motley Fool
Apr-25-19,Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release,Zacks
Apr-26-19,"Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More",Benzinga
Apr-29-19,TripAdvisor CEOs compensation plunged 95 percent in 2018,American City Business Journals
Apr-29-19,Sarepta CEO's pay dropped 98 percent in 2018,American City Business Journals
Apr-29-19,What's in the Cards for Sarepta (SRPT) This Earnings Season?,Zacks
Apr-30-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
Apr-30-19,5 Biotech Stocks for a Long-Lived Portfolio,InvestorPlace
May-01-19,"Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019",GlobeNewswire
May-02-19,Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks,GuruFocus.com
May-08-19,"Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates",Zacks
May-08-19,Sarepta Therapeutics: 1Q Earnings Snapshot,Associated Press
May-08-19,Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments,GlobeNewswire
May-08-19,"Sarepta Therapeutics, Inc. to Host Earnings Call",ACCESSWIRE
May-08-19,"Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy",GlobeNewswire
May-09-19,Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT,Thomson Reuters StreetEvents
May-09-19,"Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up",Zacks
May-09-19,"When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?",Simply Wall St.
May-10-19,Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT,Thomson Reuters StreetEvents
May-10-19,Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript,Motley Fool
May-14-19,This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note,Investor's Business Daily
May-31-19,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),GlobeNewswire
